Publications by authors named "Savani B"
Chronic graft-versus-host disease (cGVHD) represents a common long-term complication after allogeneic hematopoietic stem cell transplantation (HSCT). It imposes a significant morbidity burden and is the leading cause of non-relapse mortality among long-term HSCT survivors. cGVHD can manifest in nearly any organ, severely affecting the quality of life of a transplant survivor.
View Article and Find Full Text PDFInformation on late complications in patients with acute leukemia who have undergone allogeneic hematopoietic cell transplantation (HCT) is limited. We performed a left-truncated analysis of long-term survival in patients with acute leukemia who were alive and disease-free 2 years after HCT. We included 2701 patients with acute lymphoblastic leukemia (ALL) and 9027 patients with acute myeloid leukemia (AML) who underwent HCT between 2005 and 2012.
View Article and Find Full Text PDFArticle Synopsis
- - The neonatal Fc receptor (FcRn) plays a key role in transporting and protecting IgG antibodies, and researchers are exploring the potential of FcRn inhibitors to treat various immune-related diseases.
- - Studies indicate that FcRn inhibitors can effectively lower total IgG levels without affecting its production or the levels of other antibody types, showing promise as a safer alternative to existing immunosuppressive therapies.
- - More extensive clinical trials with diverse patient groups are needed to confirm the effectiveness and safety of FcRn inhibitors before they can become standard treatment options for hematologic conditions related to IgG antibodies.
Sexual health is an important aspect of a person's life. Many patients and haematologists believe that intimacy and sexuality issues are substantial during cancer treatment. The haematological cancer disease, diagnosis, shock of the announcement, treatment, and follow-up appointments, can all have negative effects on the quality of life of patients, their partners, other family members, and friends.
View Article and Find Full Text PDFArticle Synopsis
- * A retrospective study analyzed data from 5,790 young patients who underwent HCT to evaluate the incidence of late effects and their associated risk factors, focusing on various health complications like avascular necrosis and diabetes.
- * The study included patients from diverse backgrounds, revealing that 60.5% were male and most were white, with major findings regarding the timing and prevalence of complications occurring within five to seven years post-transplant.
Article Synopsis
- Diffuse alveolar hemorrhage (DAH) is a serious lung complication that can occur after hematopoietic cell transplantation (HCT) in patients under 21, with a low incidence rate of about 1% in this population.
- A study analyzed data from nearly 7,000 patients to identify risk factors for developing DAH, finding that nonmalignant hematologic disease, specific transplant medication regimens, and severe acute graft-versus-host disease significantly increased the risk.
- Critical care patients with DAH also showed higher instances of various health issues, including systemic and pulmonary hypertension, and other serious conditions like renal failure.
Febrile neutropenia (FN) is a complication in approximately 90% of autologous stem cell transplant (SCT) patients. Guidelines support early broad-spectrum antibiotics (BSA) to prevent morbidity and mortality. However, in patients who are clinically stable and deemed to have a fever of unknown origin, the optimal duration of BSA is unknown.
View Article and Find Full Text PDFArticle Synopsis
- * This study compared outcomes for patients over 50 years old with AML in first complete remission who received stem cell transplants from younger matched unrelated donors (MUD) versus older MRD.
- * The results showed that for patients receiving a more intense transplant conditioning regimen, younger MUDs led to better survival rates and fewer complications, making them preferable over older MRDs in this context.
Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.
Transplant Cell Ther
October 2024
Article Synopsis
- - The study investigates the survival outcomes of patients receiving umbilical cord blood transplants (UCBT) across different racial and ethnic groups, focusing on Black, Latinx, White, and Asian patients, as previous research indicated disparities in survival rates.
- - A retrospective analysis of data from the Center for International Blood and Marrow Transplant Research (CIBMTR) included 983 single and 1529 double UCBT recipients, measuring outcomes like overall survival (OS), disease-free survival, and transplant-related mortality over two years.
- - Results showed that while overall survival rates varied by race/ethnicity, with Latinx patients having significantly lower OS compared to Blacks, no significant differences were observed in child patients,
Chimeric antigen receptor (CAR) T-cell therapy has gained wide used across an array of hematologic malignancies. Though CAR T therapy has changed outcomes in the treatment of many malignancies its administration can be complicated by delays related to patient-related factors, social barriers, or insurance issues. Because of the lengthy process required to treat a patient with CAR T-cells, bridging therapy (BT), administered after leukapheresis but prior to CAR T infusion, has become an important component of safely administering CAR T therapy.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed data from patients treated with auto-HCT (281 patients) and CAR-T (79 patients) between 2015 and 2021, revealing that auto-HCT had a higher 2-year progression-free survival (66.2% vs. 47.8%) and lower relapse rate (27.8% vs. 48%).
- * The findings suggest that auto-HCT is a more effective treatment option in select patients with relapsed D
Article Synopsis
- - The study analyzed how different types of donors affect outcomes of hematopoietic cell transplantation (HCT) in patients with myelofibrosis, finding that the use of haploidentical donors rose significantly from 3% in 2013 to 19% in 2019.
- - Among 1,032 patients with chronic-phase myelofibrosis, matched sibling donor HCTs showed better overall survival in the first three months compared to haploidentical and matched unrelated donor HCTs, with notably lower rates of graft failure.
- - While matched sibling donors had superior early outcomes, there were no significant differences in long-term survival or disease-free survival among the different donor types, suggesting hap
The age effect in severe aplastic anemia (SAA) following allogeneic hematopoietic cell transplantation (HCT) favors the use of reduced intensity conditioning (RIC) regimens in older adults. We implemented a non-myeloablative regimen consisting of fludarabine, cyclophosphamide, and rituximab (FCR) to improve HCT outcomes in SAA. Patients who underwent first HCT for SAA utilizing an FCR regimen between January 2016 and May 2022 were included.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the incidence, risk factors, and outcomes of pulmonary hypertension (PH) in pediatric patients after hematopoietic stem cell transplants (HCT) conducted in a PICU setting from 2008 to 2014.
- Out of nearly 7,000 HCT patients, 29 developed PH, revealing a low overall incidence of 0.42%, but a higher prevalence of 2.72% among patients needing intensive care post-transplant.
- Key risk factors for developing PH included being Black/African American, having metabolic disorders, and a lower functional status prior to transplant, with patients experiencing significant complications and a 6-month survival rate of only 51.7% after PH diagnosis.
Hematopoietic stem cell transplantation (HSCT) is a cornerstone of modern medical practice, and can only be performed safely and effectively with appropriate transfusion medicine support. Patients undergoing HSCT often develop therapy-related cytopenia, necessitating differing blood product requirements in the pre-, peri-, and post-transplant periods. Moreover, ensuring optimal management for patients alloimmunized to human leukocyte antigens (HLA) and/or red blood cell (RBC) antigens, as well as for patients receiving ABO-incompatible transplants, requires close collaboration with transfusion medicine and blood bank professionals.
View Article and Find Full Text PDFCD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2-9).
View Article and Find Full Text PDFSecond allogeneic stem cell transplantation (alloSCT2) is among the most effective treatments for acute myeloid leukemia (AML) relapse after first alloSCT (alloSCT1). Long-term EBMT registry data were used to provide large scale, up-to-date outcome results and to identify factors for improved outcome. Among 1540 recipients of alloSCT2, increasing age, better disease control and performance status before alloSCT2, more use of alternative donors and higher conditioning intensity represented important trends over time.
View Article and Find Full Text PDFArticle Synopsis
- There has been an increase in the number of hematopoietic cell transplants (HCT) and improvement in overall survival after these procedures for blood disorders, but the impact on racial/ethnic minorities is unclear.
- A study examined transplant rates and survival trends among non-Hispanic Whites, non-Hispanic African Americans, and Hispanics from 2009 to 2018, revealing that Hispanics and non-Hispanic African Americans experienced higher rates of transplant than non-Hispanic Whites.
- Despite overall improvements in survival rates across groups, non-Hispanic African Americans faced greater mortality risks after allogeneic transplants, indicating ongoing disparities that need to be addressed.